CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 65 enrolled
Drug / intervention
Continuous Glucose Monitor +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04219085
NCT04219085N/ACompleted

CAPO: Continuous Glucose Monitoring in A2 Gestational Diabetes and Pregnancy Outcomes

Yale University·interventional·Posted Jan 6, 2020·Updated Aug 28, 2025

In Brief

A clinical study evaluating Continuous Glucose Monitor and Routine Care for Gestational Diabetes and Maternal Complication of Pregnancy. Completed, enrolled 65 participants across 1 site.

Detailed Summary

This study will utilize continuous glucose monitoring in women with A2 gestational diabetes. Women will be randomized to continuous glucose monitoring or routine care with fingersticks to check their blood glucose four times daily. It is hypothesized that women in the continuous glucose monitoring arm will have a lower incidence of the composite primary outcome, which includes the following variables: perinatal death, shoulder dystocia, birth weight greater than 4,000 grams, NICU admission for treatment of hypoglycemia (blood glucose level \<40mg/dL) and birth trauma, including fracture or nerve palsy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedJan 6, 2020
Enrollment StartSep 1, 2020
Primary CompletionAug 30, 2024
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 6.5 years ago

Interventions

Continuous Glucose Monitordevice

Wearing of a continuous glucose monitor to monitor blood glucose levels in women with gestational diabetes

Routine Careother

Use of a glucometer to monitor blood glucose levels in women with gestational diabetes